[go: up one dir, main page]

BRPI0509165A - composições de liberação prolongada compreendendo torasemida e um polìmero formador de matriz - Google Patents

composições de liberação prolongada compreendendo torasemida e um polìmero formador de matriz

Info

Publication number
BRPI0509165A
BRPI0509165A BRPI0509165-9A BRPI0509165A BRPI0509165A BR PI0509165 A BRPI0509165 A BR PI0509165A BR PI0509165 A BRPI0509165 A BR PI0509165A BR PI0509165 A BRPI0509165 A BR PI0509165A
Authority
BR
Brazil
Prior art keywords
forming polymer
torasemide
release compositions
compositions
prolonged release
Prior art date
Application number
BRPI0509165-9A
Other languages
English (en)
Inventor
Alfonso Romero
Marta Guerrero
Antonio Guglietta
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509165(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of BRPI0509165A publication Critical patent/BRPI0509165A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIçõES DE LIBERAçãO PROLONGADA COMPREENDENDO TORASEMIDA E UM POLìMERO FORMADOR DE MATRIZ. A presente invenção refere-se a composições diuréticas de liberação prolongada contendo torasemida como o ingrediente ativo. As composições da invenção são úteis por serem capazes de impedir as urgências urinárias incómodas ocasionadas por composições convencionais de liberação imediata.
BRPI0509165-9A 2004-03-25 2005-03-23 composições de liberação prolongada compreendendo torasemida e um polìmero formador de matriz BRPI0509165A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200400740A ES2244324B1 (es) 2004-03-25 2004-03-25 Composiciones diureticas de liberacion prolongada.
PCT/EP2005/051340 WO2005092291A1 (en) 2004-03-25 2005-03-23 Prolonged-release compositions comprising torasemide and a matrix-forming polymer

Publications (1)

Publication Number Publication Date
BRPI0509165A true BRPI0509165A (pt) 2007-09-11

Family

ID=34962072

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509165-9A BRPI0509165A (pt) 2004-03-25 2005-03-23 composições de liberação prolongada compreendendo torasemida e um polìmero formador de matriz

Country Status (20)

Country Link
US (1) US20080187585A1 (pt)
EP (1) EP1732517B1 (pt)
JP (1) JP4871258B2 (pt)
KR (1) KR101203763B1 (pt)
CN (1) CN1946379B (pt)
AR (1) AR048432A1 (pt)
AU (1) AU2005227095B2 (pt)
BR (1) BRPI0509165A (pt)
CA (1) CA2562142C (pt)
ES (2) ES2244324B1 (pt)
MX (1) MXPA06010833A (pt)
NO (1) NO336582B1 (pt)
PA (1) PA8627401A1 (pt)
PE (1) PE20060015A1 (pt)
PL (1) PL1732517T3 (pt)
PT (1) PT1732517T (pt)
RU (2) RU2006137671A (pt)
TW (1) TWI351957B (pt)
UY (1) UY28809A1 (pt)
WO (1) WO2005092291A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154963B2 (en) 2013-10-06 2018-12-18 Sarfez Pharmaceuticals, Inc. Controlled-release formulations comprising Torsemide
US10596119B1 (en) * 2018-11-08 2020-03-24 Sarfez Pharmaceuticals, Inc. Methods of treatment comprising torsemide
US10463622B2 (en) * 2013-10-06 2019-11-05 Sarfez Pharmaceuticals, Inc. Treatments and formulations comprising Torsemide
US12048677B2 (en) 2014-12-12 2024-07-30 Ceva Sante Animale Compositions and uses thereof for the treatment of heart failure in domestic animals
EP3031471A1 (en) * 2014-12-12 2016-06-15 Ceva Sante Animale Veterinary composition for the treatment of pulmonary edema associated with heart failure in domestic animals

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3305935C2 (de) * 1983-02-21 1985-05-30 Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn Kaliumneutrales Saluretikum mit antihypertensiver Wirkung
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
JP3586471B2 (ja) * 1991-06-25 2004-11-10 三菱ウェルファーマ株式会社 トラセミド含有医薬組成物
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
SI20816A (sl) * 1999-08-11 2002-08-31 Teva Pharmaceutical Industries Ltd. Polimorfi torsemid-a
MXPA03007908A (es) * 2000-02-17 2004-12-06 Teva Pharma Una formulacion farmaceutica estable que comprende una modificacion de torsemida ii.
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
AU2004299077A1 (en) * 2003-12-12 2005-06-30 Penwest Pharmaceuticals Co. Sustained release torsemide dosage forms

Also Published As

Publication number Publication date
UY28809A1 (es) 2005-07-29
EP1732517B1 (en) 2017-05-03
ES2244324B1 (es) 2006-11-16
TW200531693A (en) 2005-10-01
RU2006137671A (ru) 2008-04-27
CN1946379A (zh) 2007-04-11
PE20060015A1 (es) 2006-02-02
CN1946379B (zh) 2012-05-16
US20080187585A1 (en) 2008-08-07
PL1732517T3 (pl) 2017-09-29
RU2449778C1 (ru) 2012-05-10
NO336582B1 (no) 2015-09-28
EP1732517A1 (en) 2006-12-20
AR048432A1 (es) 2006-04-26
ES2244324A1 (es) 2005-12-01
PA8627401A1 (es) 2005-11-25
NO20064834L (no) 2006-12-07
AU2005227095A1 (en) 2005-10-06
AU2005227095B2 (en) 2010-10-28
CA2562142A1 (en) 2005-10-06
JP4871258B2 (ja) 2012-02-08
KR101203763B1 (ko) 2012-11-23
JP2007530510A (ja) 2007-11-01
PT1732517T (pt) 2017-08-03
KR20060130756A (ko) 2006-12-19
MXPA06010833A (es) 2006-12-15
ES2632354T3 (es) 2017-09-12
WO2005092291A1 (en) 2005-10-06
TWI351957B (en) 2011-11-11
CA2562142C (en) 2012-06-05

Similar Documents

Publication Publication Date Title
MX2009006033A (es) Composiciones y articulos que contienen una matriz de polimero reticulado y un liquido activo inmovilizado, asi como metodos para fabricarlos.
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
WO2008084495A3 (en) Novel agricultural composition
WO2007122581A3 (en) Compositions and kits of phenylephrine
CR11581A (es) Composiciones en forma de comprimidos bucodispersables de temazepan
WO2008009379A3 (de) Wirkstoffkombinationen mit insektiziden und akariziden eigenschaften
BRPI0514665A2 (pt) compostos com atividade antibacteriana, composições farmacêuticas e uso dos mesmos
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
IL185542A0 (en) Compositions having sustained -release insect repellency
TW200621268A (en) Antimicrobial copolymers and uses thereof
CR9114A (es) 2-alcoxi-3,4,5-trihydroxi-alquimidas, su preparacion composicones que las contienen y su utilizacion
AR051128A1 (es) Composiciones encapsuladas para activos, termicamente estables, altamente resistentes
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
CY1109209T1 (el) Μητρες ανιονικης υδρογελης με ph-εξαρτωμενη τροποιημενη αποδεσμευση ως μεταφορεις φαρμακων
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
BRPI0509165A (pt) composições de liberação prolongada compreendendo torasemida e um polìmero formador de matriz
EA201100753A1 (ru) Композиции с пролонгированным высвобождением, содержащие производное 2-оксо-1-пирролидина
TR200902923T2 (tr) Megestrol maddenin farmasötik olarak kararlı bir süspansiyonu.
CR9231A (es) Pirroles sustituidos, composiciones que los contienen, procesos de fabricacion y utilizacion
WO2008060865A3 (en) Compositions and methods for reducing antimicrobial resistance of microbes
WO2009084020A3 (en) Topical composition comprising halobetasol and salicylic acid
GT200600121A (es) Novedosos derivados de triazolopirimidina
TW200700008A (en) Herbicidal compositions based on 3-phenyluracils and 3-sulfonylisoxazolines
CR10382A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzazepinas, su preparacion, composiciones que las contienen y utilizacion
CR10428A (es) 2-alcoxi-3,4,5-trihidroxi-alquilamida-benzotiazepinas, su preparacion, composiciones que las contienen y utilizacion

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL